Zacks Investment Research upgraded shares of BioLineRx Ltd. (NASDAQ:BLRX) from a hold rating to a buy rating in a research report released on Tuesday. They currently have $1.25 price objective on the biotechnology company’s stock.

According to Zacks, “Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company’s portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. “

Several other equities research analysts also recently commented on BLRX. Maxim Group set a $3.00 price objective on BioLineRx and gave the company a buy rating in a report on Monday, July 10th. ValuEngine upgraded BioLineRx from a sell rating to a hold rating in a report on Monday, July 17th. Roth Capital started coverage on BioLineRx in a report on Thursday, August 3rd. They set a buy rating and a $3.00 price objective for the company. Oppenheimer Holdings, Inc. started coverage on BioLineRx in a report on Friday, August 4th. They set an outperform rating and a $3.00 price objective for the company. Finally, HC Wainwright set a $4.00 price objective on BioLineRx and gave the company a buy rating in a report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. The stock currently has an average rating of Buy and an average target price of $2.88.

Shares of BioLineRx (BLRX) traded up 0.38% during trading on Tuesday, hitting $1.31. The company had a trading volume of 100,055 shares. The stock’s market capitalization is $125.26 million. BioLineRx has a 12-month low of $0.80 and a 12-month high of $1.42. The stock has a 50-day moving average of $1.09 and a 200 day moving average of $0.97.

BioLineRx (NASDAQ:BLRX) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.05) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.05). On average, analysts predict that BioLineRx will post ($0.24) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/10/06/biolinerx-ltd-blrx-lifted-to-buy-at-zacks-investment-research.html.

Several large investors have recently made changes to their positions in the stock. Sabby Management LLC purchased a new position in shares of BioLineRx during the first quarter valued at approximately $3,018,000. KCG Holdings Inc. boosted its position in shares of BioLineRx by 715.9% during the first quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 153,687 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of BioLineRx during the first quarter valued at approximately $126,000. Finally, Citadel Advisors LLC boosted its position in shares of BioLineRx by 443.4% during the first quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 86,481 shares during the last quarter. 32.27% of the stock is currently owned by institutional investors.

About BioLineRx

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

Get a free copy of the Zacks research report on BioLineRx (BLRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for BioLineRx (NASDAQ:BLRX)

Receive News & Stock Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related stocks with our FREE daily email newsletter.